-
21دورية أكاديمية
المؤلفون: Dimitrios C. Ziogas, Charalampos Theocharopoulos, Panagiotis-Petros Lialios, Dimitra Foteinou, Ioannis-Alexios Koumprentziotis, Georgios Xynos, Helen Gogas
المصدر: Cancers; Volume 15; Issue 10; Pages: 2718
مصطلحات موضوعية: immune checkpoints, immune checkpoint inhibitors, melanoma, immunotherapy resistance, relatlimab, LAG-3, TIGIT, TIM-3, VISTA
وصف الملف: application/pdf
العلاقة: Cancer Immunology and Immunotherapy; https://dx.doi.org/10.3390/cancers15102718Test
-
22دورية أكاديمية
المؤلفون: Raquel Gil-Edo, German Hernández-Ribelles, Santiago Royo, Natasha Thawait, Alan Serrels, Miguel Carda, Eva Falomir
المصدر: International Journal of Molecular Sciences; Volume 24; Issue 10; Pages: 8582
مصطلحات موضوعية: aryl urea, benzylethoxyaryl urea, angiogenesis, PD-L1, VEGFR-2, TLCRs, immune checkpoints, PD-1, TIM-3, LAG-3, CD11b, CD69, OX-40, CD8+ T cell, LCK, Fyn, LAT, ZAP70
جغرافية الموضوع: agris
وصف الملف: application/pdf
العلاقة: Molecular Oncology; https://dx.doi.org/10.3390/ijms24108582Test
-
23دورية أكاديمية
المؤلفون: Christina Bruss, Kerstin Kellner, Veruschka Albert, James A. Hutchinson, Stephan Seitz, Olaf Ortmann, Gero Brockhoff, Anja K. Wege
المصدر: Cancers; Volume 15; Issue 9; Pages: 2615
مصطلحات موضوعية: humanized tumor mice (HTM), breast cancer, hematopoietic stem cells (HSC), TIM-3, LAG-3, galectin-9, PD-1, PD-L1, soluble checkpoint, immunotherapy
وصف الملف: application/pdf
العلاقة: Cancer Immunology and Immunotherapy; https://dx.doi.org/10.3390/cancers15092615Test
-
24دورية أكاديمية
المؤلفون: Andrew Knight, Lilit Karapetyan, John M. Kirkwood
المصدر: Cancers; Volume 15; Issue 4; Pages: 1106
مصطلحات موضوعية: melanoma, immunotherapy, immune checkpoint blockade, LAG-3, TLR-9, STING, T-VEC, fecal microbiota transplant, adoptive cell therapy
وصف الملف: application/pdf
العلاقة: Cancer Immunology and Immunotherapy; https://dx.doi.org/10.3390/cancers15041106Test
-
25دورية أكاديمية
المؤلفون: Matyas Meggyes, Timoteus Feik, David U. Nagy, Beata Polgar, Laszlo Szereday
المصدر: International Journal of Molecular Sciences; Volume 24; Issue 2; Pages: 1390
مصطلحات موضوعية: NKT, immune checkpoint, PD-1, LAG-3, TIGIT, preeclampsia
جغرافية الموضوع: agris
وصف الملف: application/pdf
العلاقة: Molecular Immunology; https://dx.doi.org/10.3390/ijms24021390Test
-
26دورية أكاديمية
المصدر: Viruses; Volume 15; Issue 1; Pages: 147
مصطلحات موضوعية: LAG-3, Ligand, T cell dysfunction, viral infections
جغرافية الموضوع: agris
وصف الملف: application/pdf
العلاقة: Viral Immunology, Vaccines, and Antivirals; https://dx.doi.org/10.3390/v15010147Test
-
27دورية أكاديمية
المؤلفون: O. N. Selyutina, I. B. Lysenko, N. K. Guskova, I. A. Novikova, E. Yu. Zlatnik, T. F. Pushkareva, N. V. Nikolaeva, I. A. Kamaeva, N. Yu. Samaneva, E. A. Kapuza, О. Н. Селютина, И. Б. Лысенко, Н. К. Гуськова, И. А. Новикова, Е. Ю. Златник, Т. Ф. Пушкарева, Н. В. Николаева, И. А. Камаева, Н. Ю. Саманева, Е. А. Капуза
المصدر: Siberian journal of oncology; Том 22, № 2 (2023); 34-42 ; Сибирский онкологический журнал; Том 22, № 2 (2023); 34-42 ; 2312-3168 ; 1814-4861
مصطلحات موضوعية: иммунохимиотерапия, flow cytometry, LAG-3, minimal residual disease, immunophenotypic prognostic markers, immunochemotherapy, проточная цитофлуориметрия, минимальная остаточная болезнь, иммунофенотипические прогностические маркеры
وصف الملف: application/pdf
العلاقة: https://www.siboncoj.ru/jour/article/view/2527/1093Test; Kipps T.J., Stevenson F.K., Wu C.J., Croce C.M., Packham G., Wierda W.G., O’Brien S., Gribben J., Rai K. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017; 3: 1–22. doi:10.1038/nrdp.2016.96.; Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005; 352(8): 804–15. doi:10.1056/NEJMra041720.; Yosifov D.Y., Wolf C., Stilgenbauer S., Mertens D. From Biology to Therapy: The CLL Success Story. Hemasphere. 2019; 3(2). doi:10.1097/HS9.0000000000000175.; Кравченко Д.В., Свирновский А.И. Хронический лимфоцитарный лейкоз: клиника, диагностика, лечение. Гомель, 2017. 117 с.; Craig F.E., Foon K.A. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008; 111(8): 3941–67. doi:10.1182/blood-2007-11-120535.; Гуськова Н.К., Селютина О.Н., Новикова И.А., Максимов А.Ю., Ноздричева А.С., Абакумова С.В. Морфологические и иммунофенотипические особенности моноклональной популяции В-лимфоцитов при хроническом лимфолейкозе. Южно-Российский онкологический журнал. 2020; 1(3): 27–35. doi:10.37748/2687-0533-2020-1-3-3.; Rodríguez-Vicente A.E., Díaz M.G., Hernández-Rivas J.M. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. Cancer Genet. 2013; 206(3): 49–62. doi:10.1016/j.cancergen.2013.01.003.; Eichhorst B., Robak T., Montserrat E., Ghia P., Niemann C.U., Kater A.P., Gregor M., Cymbalista F., Buske C., Hillmen P., Hallek M., Mey U.; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(1): 23–33. doi:10.1016/j.annonc.2020.09.019.; Baliakas P., Mattsson M., Stamatopoulos K., Rosenquist R. Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed? J Intern Med. 2016; 279(4): 347–57. doi:10.1111/joim.12455.; Brown J.R., Hillmen P., O’Brien S., Barrientos J.C., Reddy N.M., Coutre S.E., Tam C.S., Mulligan S.P., Jaeger U., Barr P.M., Furman R.R., Kipps T.J., Cymbalista F., Thornton P., Caligaris-Cappio F., Delgado J., Montillo M., DeVos S., Moreno C., Pagel J.M., Munir T., Burger J.A., Chung D., Lin J., Gau L., Chang B., Cole G., Hsu E., James D.F., Byrd J.C. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018; 32(1): 83–91. doi:10.1038/leu.2017.175.; Taghiloo S., Allahmoradi E., Ebadi R., Tehrani M., HosseiniKhah Z., Janbabaei G., Shekarriz R., Asgarian-Omran H. Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia. Asian Pac J Cancer Prev. 2017; 18(8): 2269–74. doi:10.22034/APJCP.2017.18.8.2269.; Mohammed Basabaeen A.A., Abdelgader E.A., Babekir E.A., Abdelrahim S.O., Eltayeb N.H., Altayeb O.A., Fadul E.A., Sabo A., Ibrahim I.K. TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population. Asian Pac J Cancer Prev. 2019; 20(5): 1579–85. doi:10.31557/APJCP.2019.20.5.1579.; Joshi N.S., Cui W., Chandele A., Lee H.K., Urso D.R., Hagman J., Gapin L., Kaech S.M. Inflammation directs memory precursor and short-lived efector CD8(+) T cell fates via the graded expression of Tbet transcription factor. Immunity. 2007; 27(2): 281–95. doi:10.1016/j.immuni.2007.07.010.; Fischer K., Bahlo J., Fink A.M., Goede V., Herling C.D., Cramer P., Langerbeins P., von Tresckow J., Engelke A., Maurer C., Kovacs G., Herling M., Tausch E., Kreuzer K.A., Eichhorst B., Böttcher S., Seymour J.F., Ghia P., Marlton P., Kneba M., Wendtner C.M., Döhner H., Stilgenbauer S., Hallek M. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016; 127(2): 208–15. doi:10.1182/blood-2015-06-651125.; Fischer K., Cramer P., Busch R., Böttcher S., Bahlo J., Schubert J., Pfüger K.H., Schott S., Goede V., Isfort S., von Tresckow J., Fink A.M., Bühler A., Winkler D., Kreuzer K.A., Staib P., Ritgen M., Kneba M., Döhner H., Eichhorst B.F., Hallek M., Stilgenbauer S., Wendtner C.M. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012; 30(26): 3209–16. doi:10.1200/JCO.2011.39.2688.; Eichhorst B., Fink A.M., Bahlo J., Busch R., Kovacs G., Maurer C., Lange E., Köppler H., Kiehl M., Sökler M., Schlag R., Vehling-Kaiser U., Köchling G., Plöger C., Gregor M., Plesner T., Trneny M., Fischer K., Döhner H., Kneba M., Wendtner C.M., Klapper W., Kreuzer K.A., Stilgenbauer S., Böttcher S., Hallek M.; international group of investigators; German CLL Study Group (GCLLSG). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016; 17(7): 928–42. doi:10.1016/S1470-2045(16)30051-1.; Al-Sawaf O., Hallek M., Fischer K. The role of minimal residual disease in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2022; 20(2): 97–103.; Böttcher S., Ritgen M., Fischer K., Stilgenbauer S., Busch R.M., Fingerle-Rowson G., Fink A.M., Bühler A., Zenz T., Wenger M.K., Men-dila M., Wendtner C.M., Eichhorst B.F., Döhner H., Hallek M.J., Kneba M. Minimal residual disease quantifcation is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012; 30(9): 980–8. doi:10.1200/JCO.2011.36.9348.; Goede V., Fischer K., Busch R., Engelke A., Eichhorst B., Wendtner C.M., Chagorova T., de la Serna J., Dilhuydy M.S., Illmer T., Opat S., Owen C.J., Samoylova O., Kreuzer K.A., Stilgenbauer S., Döhner H., Langerak A.W., Ritgen M., Kneba M., Asikanius E., Humphrey K., Wenger M., Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014; 370(12): 1101–10. doi:10.1056/NEJMoa1313984.; Kovacs G., Robrecht S., Fink A.M., Bahlo J., Cramer P., von Tresckow J., Maurer C., Langerbeins P., Fingerle-Rowson G., Ritgen M., Kneba M., Döhner H., Stilgenbauer S., Klapper W., Wendtner C.M., Fischer K., Hallek M., Eichhorst B., Böttcher S. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. J Clin Oncol. 2016; 34(31): 3758–65. doi:10.1200/JCO.2016.67.1305.; Dimier N., Delmar P., Ward C., Morariu-Zamfr R., Fingerle-Rowson G., Bahlo J., Fischer K., Eichhorst B., Goede V., van Dongen J.J.M., Ritgen M., Böttcher S., Langerak A.W., Kneba M., Hallek M. A model for predicting efect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018; 131(9): 955–62. doi:10.1182/blood-2017-06-792333.; Molica S., Giannarelli D., Montserrat E. Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2019; 19(7): 423–30. doi:10.1016/j.clml.2019.03.014.; Huard B., Tournier M., Hercend T., Triebel F., Faure F. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur J Immunol. 1994; 24(12): 3216–21. doi:10.1002/eji.1830241246.; Shapiro M., Herishanu Y., Katz B.Z., Dezorella N., Sun C., Kay S., Polliack A., Avivi I., Wiestner A., Perry C. Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia. Haematologica. 2017; 102(5): 874–82. doi:10.3324/haematol.2016.148965.; Kotaskova J., Tichy B., Trbusek M., Francova H.S., Kabathova J., Malcikova J., Doubek M., Brychtova Y., Mayer J., Pospisilova S. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival. J Mol Diagn. 2010; 12(3): 328–34. doi:10.2353/jmoldx.2010.090100.; Никитин Е.А., Бялик Т.Е., Зарицкий А.Ю., Исебер Л., Капланов К.Д., Лопаткина Т.Н., Луговская С.А., Мухортова О.В., Османов Е.А., Поддубная И.В., Самойлова О.С., Стадник Е.А., Фалалеева Н.А., Байков В.В., Ковригина А.М., Невольских А.А., Иванов С.А., Хайлова Ж.В., Геворкян Т.Г. Хронический лимфоцитарный лейкоз/лимфома из малых лимфоцитов. Клинические рекомендации. Современная Онкология. 2020; 22(3): 24–44. doi:10.26442/18151434.2020.3.200385.; Rawstron A.C., Villamor N., Ritgen M., Böttcher S., Ghia P., Zehnder J.L., Lozanski G., Colomer D., Moreno C., Geuna M., Evans P.A., Natkunam Y., Coutre S.E., Avery E.D., Rassenti L.Z., Kipps T.J., CaligarisCappio F., Kneba M., Byrd J.C., Hallek M.J., Montserrat E., Hillmen P. International standardized approach for fow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007; 21(5): 956–64. doi:10.1038/sj.leu.2404584.; Кит О.И., Тимофеева С.В., Ситковская А.О., Новикова И.А., Колесников Е.Н. Биобанк ФГБУ «НМИЦ онкологии» Минздрава России как ресурс для проведения исследований в области персонифицированной медицины. Современная онкология. 2022; 24(1): 6–11. doi:10.26442/18151434.2022.1.201384.; Wierz M., Pierson S., Guyonnet L., Viry E., Lequeux A., Oudin A., Niclou S.P., Ollert M., Berchem G., Janji B., Guérin C., Paggetti J., Moussay E. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. Blood. 2018; 131(14): 1617–21. doi:10.1182/blood-2017-06-792267.; Sordo-Bahamonde C., Lorenzo-Herrero S., González-Rodríguez A.P., Payer Á.R., González-García E., López-Soto A., Gonzalez S. LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia. Cancers (Basel). 2021; 13(9): 2112. doi:10.3390/cancers13092112.; Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M., Nirschl C.J., Bettini M.L., Gravano D.M., Vogel P., Liu C.L., Tangsombatvisit S., Grosso J.F., Netto G., Smeltzer M.P., Chaux A., Utz P.J., Workman C.J., Pardoll D.M., Korman A.J., Drake C.G., Vignali D.A. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012; 72(4): 917–27. doi:10.1158/0008-5472.CAN-11-1620.; Grosso J.F., Kelleher C.C., Harris T.J., Maris C.H., Hipkiss E.L., De Marzo A., Anders R., Netto G., Getnet D., Bruno T.C., Goldberg M.V., Pardoll D.M., Drake C.G. LAG-3 regulates CD8+ T cell accumulation and efector function in murine self- and tumor-tolerance systems. J Clin Invest. 2007; 117(11): 3383–92. doi:10.1172/JCI31184.; Qi Y., Chen L., Liu Q., Kong X., Fang Y., Wang J. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Efective Immunotherapy Strategy. Front Immunol. 2021; 11. doi:10.3389/fmmu.2020.563258.; Liu D. Cancer biomarkers for targeted therapy. Biomark Res. 2019; 7: 25. doi:10.1186/s40364-019-0178-7.; Grzywnowicz M., Karabon L., Karczmarczyk A., Zajac M., Skorka K., Zaleska J., Wlasiuk P., Chocholska S., Tomczak W., BojarskaJunak A., Dmoszynska A., Frydecka I., Giannopoulos K. The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(10): 2908–13. doi:10.3109/10428194.2015.1017820.; Li M., Sun X.H., Zhu X.J., Jin S.G., Zeng Z.J., Zhou Z.H., Yu Z., Gao Y.Q. HBcAg induces PD-1 upregulation on CD4+T cells through activation of JNK, ERK and PI3K/AKT pathways in chronic hepatitisB-infected patients. Lab Invest. 2012; 92(2): 295–304. doi:10.1038/labinvest.2011.157.; McClanahan F., Riches J.C., Miller S., Day W.P., Kotsiou E., Neuberg D., Croce C.M., Capasso M., Gribben J.G. Mechanisms of PDL1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model. Blood. 2015; 126(2): 212–21. doi:10.1182/blood-2015-02-626754.; Ramsay A.G., Clear A.J., Fatah R., Gribben J.G. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012; 120(7): 1412–21. doi:10.1182/blood-2012-02-411678.; Табаков Д.В., Заботина Т.Н., Чантурия Н.В., Захарова Е.Н., Воротников И.К., Сельчук В.Ю., Соколовский В.В., Петровский А.В. Взаимосвязь экспрессии GITR, Lag-3 и PD-1 с основными показателями системного и локального иммунитета у больных раком молочной железы. Современная онкология. 2021; 23(3): 457–65. doi:10.26442/18151434.2021.3.200809.; Wang Q., Zhang J., Tu H., Liang D., Chang D.W., Ye Y., Wu X. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients. J Immunother Cancer. 2019; 7(1): 334. doi:10.1186/s40425-019-0810-y.; He Y., Wang Y., Zhao S., Zhao C., Zhou C., Hirsch F.R. sLAG-3 in non-small-cell lung cancer patients’ serum. Onco Targets Ther. 2018; 11: 4781–4. doi:10.2147/OTT.S164178.; Eichhorst B., Fink A.M., Busch R., Kovacs G., Maurer C., Lange E., Köppler H., Kiehl M.G., Soekler M., Schlag R., Vehling-Kaiser U., Köchling G.R.A., Plöger C., Gregor M., Plesner T., Trneny M., Fischer K., Döhner H., Kneba M., Wendtner C.M., Klapper W., Kreuzer K.A., Stilgenbauer S., Böttcher S., Hallek M. Frontline chemoimmunotherapy with fudarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efcacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically ft patients (pts) with advanced chronic lymphocytic leukemia (CLL): Final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 study). Blood. 2014; 124 (21): 19. doi:10.1182/blood.V124.21.19.19.; https://www.siboncoj.ru/jour/article/view/2527Test
الإتاحة: https://doi.org/10.21294/1814-4861-2023-22-2-34-42Test
https://doi.org/10.1038/nrdp.2016.96Test
https://doi.org/10.1056/NEJMra041720Test
https://doi.org/10.1097/HS9.0000000000000175Test
https://doi.org/10.1182/blood-2007-11-120535Test
https://doi.org/10.37748/2687-0533-2020-1-3-3Test
https://doi.org/10.1016/j.cancergen.2013.01.003Test
https://doi.org/10.1016/j.annonc.2020.09.019Test
https://doi.org/10.1038/leu.2017.175Test
https://doi.org/10.22034/APJCP.2017.18.8.2269Test -
28دورية أكاديمية
المؤلفون: Hyunjee Lee, Sang Eun Yoon, Seok Jin Kim, Won Seog Kim, Junhun Cho
المصدر: Cancer Medicine, Vol 12, Iss 15, Pp 16359-16369 (2023)
مصطلحات موضوعية: CD274, diffuse large B‐cell lymphoma, immune checkpoint, LAG3, LAG‐3, PD‐L1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
العلاقة: https://doi.org/10.1002/cam4.6268Test; https://doaj.org/toc/2045-7634Test; https://doaj.org/article/4ce3c97660b24e068912b1aa4cba0da8Test
الإتاحة: https://doi.org/10.1002/cam4.6268Test
https://doaj.org/article/4ce3c97660b24e068912b1aa4cba0da8Test -
29دورية أكاديمية
المؤلفون: Natalia Kreiniz, Nasren Eiza, Tamar Tadmor, Ilana Levy Yurkovski, Sarah Matarasso Greenfeld, Adi Sabag, Raeda Mubariki, Celia Suriu, Ekaterina Votinov, Elias Toubi, Zahava Vadasz
المصدر: International Journal of Molecular Sciences, Vol 25, Iss 1, p 549 (2023)
مصطلحات موضوعية: multiple myeloma (MM), Lymphocyte-Activation Protein 3 (LAG-3), regulatory molecules, Cluster of Differentiation-8 (CD8), hematological malignancies, plasma cells, Biology (General), QH301-705.5, Chemistry, QD1-999
العلاقة: https://www.mdpi.com/1422-0067/25/1/549Test; https://doaj.org/toc/1661-6596Test; https://doaj.org/toc/1422-0067Test; https://doaj.org/article/5650209eec6448358d291159fc694dfdTest
الإتاحة: https://doi.org/10.3390/ijms25010549Test
https://doaj.org/article/5650209eec6448358d291159fc694dfdTest -
30دورية أكاديمية
المؤلفون: Tuba N. Gide, Elizabeth C. Paver, Zarwa Yaseen, Nigel Maher, Nurudeen Adegoke, Alexander M. Menzies, Ines Pires da Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer
المصدر: OncoImmunology, Vol 12, Iss 1 (2023)
مصطلحات موضوعية: LAG-3, biomarker, immune checkpoint inhibitors, immunotherapy, melanoma, Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
العلاقة: https://doaj.org/toc/2162-402XTest; https://doaj.org/article/de51474a80d24f65bee9d63be6c7447fTest
الإتاحة: https://doi.org/10.1080/2162402X.2023.2261248Test
https://doaj.org/article/de51474a80d24f65bee9d63be6c7447fTest